Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored associations between CF and medical and psychosocial variables. A population-based, cross-sectional postal survey in 2006 included Norwegian hormone-naïve survivors with the diagnosis of prostate cancer in 2004 who were treated with RP (n ¼ 337) or RAD (n ¼ 184). The primary outcome variable was prevalence of CF (defined as fatigue lasting 6 months or longer). Twelve to 32 months after RP and RAD, 13.4 and 26.1% of the patients after, respectively, RP and RAD reported CF inversely associated with pretreatment age (P ¼ 0.003). In multivariate analysis, high neuroticism, post-treatment co-morbidity, pain, urinary and intestinal dysfunction, but not sexual dysfunction, were positively associated with reporting CF. Further studies of CF in prostate cancer survivors should take into consideration the survivors' pretreatment medical and psychosocial situation.
Introduction
Radical prostatectomy (RP) and definitive radiotherapy (RAD), the latter often combined with transient androgen-deprivation therapy (ADT), represent the standard curative treatments for prostate cancer, with similar survival rates among patients with comparable extent of the disease.
1,2 Pretreatment information on treatmentrelated morbidity, in particular about the persistence of late adverse effects, influences the patients' final decision concerning therapy. 3, 4 Today the risk of 'typical adverse effects' (urinary incontinence, erectile and intestinal dysfunction) is probably discussed with the patient on a regular basis. However, it is more uncertain at what degree other dimensions of post-treatment survivorship such as quality of life, work ability and fatigue are issues of pretreatment counseling.
Fatigue is a multidimensional symptom defined by the European Association of Palliative Care as 'the subjective feeling of tiredness, weakness or lack of energy'. 5 Clinically significant levels of fatigue lasting for more than 6 months have been referred to as chronic fatigue (CF) and are found in 10% of the general Norwegian male population 6 and in 17-31% of male cancer survivors. 7, 8 The prevalence of fatigue as a late adverse effect after treatment for localized prostate cancer is 15-40% after RAD 9-13 and 10-17% after RP. 9, 10, 13 However, there are differences in the definition of fatigue, followup time and heterogeneity of samples explaining the variation in prevalence figures. In particular, fatigue has rarely been studied in hormone-naïve prostate cancer survivors after RP and RAD, and no study has examined CF in such samples.
The primary aim of our exploratory study was to investigate the prevalence of CF in hormone-naïve prostate cancer survivors who had undergone RP or RAD at least 1 year prior to the survey. The secondary aim was to study associations between CF and medical and psychosocial variables.
Materials and methods

National health registries
All new cases of cancer in Norway have to be reported to the Cancer Registry of Norway (CRN) by law.
14 In 2004 the CRN established a sub-registry for prostate cancer, the Norwegian Prostate Cancer Registry, with extended information on diagnostics and treatment, although without sufficient information on the use of ADT. For the present study, TNM category, PSA, Gleason score, age and the start of RP and RAD were retrieved from the Norwegian Prostate Cancer Registry.
Since January 1, 2004, the National Prescription Database (NorPD) has collected person-identifiable information on all medications prescribed. For prostate cancer patients diagnosed in 2004, any initiation of ADT thus can be monitored together with the use of medications for chronic non-malignant conditions. Since data from both CRN and NorPD are collected using the unique personal number given to all Norwegian citizens, the person-identified records from these two registries were linked together reflecting each person's use of medications. NorPD data were released only for men who had consented to project participation.
Study population
The present study is a part of a national cross-sectional pattern of care study, which assesses the treatment and outcome of Norwegian prostate cancer patients diagnosed in 2004 according to the CRN. 15 In October 2006, patients still alive (n ¼ 2998) were invited to participate in a cross-sectional postal survey with 2194 respondents (compliance rate 73%). For the present study, a subgroup was selected (n ¼ 531) containing survivors for whom X12 months had elapsed since the start of curative treatment and who never had undergone orchiectomy or ADT prior to the survey, according to patients' selfreport and data from NorPD.
CF and variables in study
Chronic fatigue was the primary outcome variable of this study and was assessed using The Fatigue Questionnaire. 16 The Fatigue Questionnaire evaluates physical fatigue and mental fatigue and the Total Fatigue Score is calculated by summarizing the scores of physical fatigue and mental fatigue. Higher scores imply more fatigue. CF was defined as a sum score of X4 after dichotomization of the Fatigue Questionnaire symptom scores and duration for X6 months. 19 and medication for chronic diseases reflecting pretreatment co-morbidity (0, no medication for chronic disease; 1, medication for one chronic disease; 2, medication for two or more chronic diseases).
The following additional instruments were used ( have shown that the total BSFI score can serve as an overall measure of sexuality, excluding overall satisfaction. A higher BSFI total score implies better sexual function, and the range is from 0 to 40.
Bodily pain was rated by one item of the SF-12. We added a question about bother related to pain, to form a dichotomous variable called 'pain' (0, no pain or bother related to pain (No); 1, any degree of pain and/or any degree of bother from pain (Yes)).
We used an abbreviated version of the Eysenck Personality Questionnaire (EPQ-18) [22] [23] [24] [25] to measure neuroticism. Six items comprise the personality trait neuroticism that covers the dimension from feeling nervous to feeling safe ( Pretreatment medication 0, no medication for chronic illness before and until three months after treatment 1, prescription for one chronic illness before treatment and until three months after treatment 2, prescription for two or more chronic illnesses before treatment and until three months after treatment
At survey Treatment 0, radical prostatectomy; 1, definitive radiotherapy Observation time
Months between treatment start and survey in three subcategories. 0: 12, o20 months; 1: 20, o26 months; 2: 26, o32 months Neuroticism Abbreviated Eysenck Personality Questionnaire, continuous 0-6; higher score means more nervousness. 22 Low neuroticism, score 0-4; high neuroticism, score 5-6. Co-morbidity 0, 0-1 co-morbid illnesses; 1, X2 co-morbid illnesses Lifestyle 0, non-smoker, BMIp30 and physical activity as recommended by the American College of Sports Medicine; 28 1, daily smoker, BMI430, or physical activity less than recommended Pain 0, no pain; 1, any degree of pain and/or any degree of bother from pain Urinary dysfunction 0, IPSS score o20 and urine leakage less than once a day 1, IPSS score 20-35 or leaking urine at least once a day Intestinal dysfunction 0, none of the dysfunctions mentioned below; 1, at least one of the following traits: (1) defecation X3 times a day; (2) at least 50% of the time; diarrhea, blood or mucus in stool or painful defecation 50% of the time; (3) X2 times a week cramps or fecal urgency, or fecal leakage once a week or more Sexual function Brief Sexual Function Inventory, total score, continuous 0-40; higher score means better sexual function. 27 assessed urinary function, except leakage. We therefore added a question as to the prevalence and severity of urine leakage ( Table 1) .
The questionnaire also contained items covering the following dimensions:
Intestinal dysfunction as defined in Table 1 ; comorbidity: affirmative response to questions about the presence of two or more of 19 medical conditions was defined as presence of co-morbidity (Table 1) . Lifestyle was dichotomized into 'healthy' and 'unhealthy' ( Table 1) .
Level of education and relationship status were assessed at the time of the survey. They were not expected to have changed since diagnosis and were therefore treated as pretreatment observations.
Statistical analyses
Continuous variables were described with median and range, and if normally distributed, with mean and standard deviation (s.d.). Categorical variables were described with proportions and percentages. Continuous data were compared using t-tests if normally distributed and Mann-Whitney tests for skewed distributions. Categorical data were compared using w 2 -tests. The associations between presence or absence of CF (dependent) and the other measured variables (independent) were modeled using logistic regression. Independent variables that showed statistically significant associations with CF in univariate analyses were included in a multivariate logistic regression model. The strength of association was expressed as odds ratios with 95% confidence intervals (95% CI). The level of significance was set at a ¼ 0.05, and all test were two-sided. All analyses were performed using SPSS version 15.0 (Chicago, IL, USA).
Ethics
Approval of the study was obtained from the Regional Ethical Committee, and all participants gave written informed consent.
Results
Patient sample
A total of 531 patients were eligible for the study and 521 returned a completed questionnaire (RP, n ¼ 337; RAD, n ¼ 184). The median observation time was 23 months (range, 12-32) and median age was 65 years (range, 44-75). Patients who received RAD were older at diagnosis than patients undergoing RP (Po0.001) ( Table 2) , and they also more often belonged to a higher D'Amico risk group mainly due to significantly higher PSA at diagnosis (Po0.05). Biopsy Gleason score and clinical T-category did not differ between the treatment groups. Use of any pretreatment medication for chronic diseases did not differ between the RP and the RAD group (P ¼ 0.11).
Post-treatment characteristics
Almost 80% of the patients had an observation time of 20 months or longer. At the time of the survey, significantly more patients from the RAD than from the RP group reported post-treatment co-morbidity and pain (Table 3A) . Compared with the RP group, fewer survivors after RAD had urinary dysfunction, but they more often had intestinal dysfunction (Table 3B) .
At the time of survey, 17.9% of the prostate cancer survivors reported CF (n ¼ 93); 13.4% after RP (95% CI 9.7-17.0) and 26.1% after RAD (95% CI 19.6-32.4), with significantly increased values of physical fatigue, mental fatigue and Total Fatigue Score in the RAD group as compared with those in the RP group (Table 3C) . The difference in CF prevalence between RP and RAD was most prominent in survivors with the longest observation time, with 36% CF after RAD and 10% after RP (Po0.001) (Figure 1 ).
Logistic regression analyses
In univariate analyses, variables with significant associations with CF were type of treatment, age at diagnosis, pretreatment medication, neuroticism, co-morbidity, lifestyle, pain and urinary, and intestinal and sexual function (Table 4 ). In the multivariate analysis, survivors Fatigue in hormone-naïve prostate cancer survivors AE Kyrdalen et al after RAD were twice as likely to report CF as compared with RP (Table 4) . Younger age was significantly associated with post-treatment CF. For a 5-year increase in age the odds of CF were reduced by almost 30% (data not shown). High neuroticism, presence of co-morbidity, pain and urinary and intestinal dysfunction remained positively and significantly associated with CF in the multivariate analyses.
Discussion
The overall prevalence of CF was 26.1% after RAD and 13.4% after RP, with the greatest difference in survivors with the longest observation times (Figure 1) . Younger age at diagnosis, high neuroticism, presence of pain, post-treatment co-morbidity and urinary and intestinal dysfunction were significantly associated with CF in the multivariate analysis, with the highest numerical point estimate for high neuroticism. Fatigue or loss of vitality, to a certain degree reflecting fatigue, has been reported in several surveys of prostate cancer survivors, [9] [10] [11] [12] [13] often assessed as a dimension of a generic QoL instrument such as the RAND 36-Item Health Survey (SF-36) or the EORTC QLQ C30. However, in most studies patients who never received ADT cannot be separated from those with previous or ongoing hormone treatment. As ADT is highly associated with fatigue, 29, 30 such separations are necessary when the role of local treatment is to be evaluated. Monga et al., 12 in a study meeting this requirement, found the rate of severe fatigue to be 40% among RAD patients with no initial ADT, at a mean time of 16.2 months after initiation of RAD, however, without identification of current hormone users. Our observations add to the results of these studies of fatigue in prostate cancer survivors, [9] [10] [11] [12] [13] showing that fatigue is a problem after local treatment even in patients without ADT.
The overall prevalence of long-term CF in 26.1% of our RAD patients represents a new finding, although the 95% CIs of CF in the RP and RAD groups did not differ significantly from that observed in the Norwegian male general population aged X60 years (16.8%; 95% CI 11.7-21.1). 6 The comparison with figures from the general population must, however, be interpreted with caution: RP and RAD are probably offered to men who are healthier and less fatigued than the 'average male' of the same age category. 31 With this background our explanatory suggestion is that even small decreases in fatigue and vitality post-treatment might be felt as significant reduction in general well-being, in individuals with better general health than in the age-matched general population.
High neuroticism has been identified as a risk factor for fatigue 32 and is associated with CF in the general population. 33 In our multivariate analysis, high neuroticism had the greatest numerical point estimate of odds ratio, which indicates a particularly strong association with post-treatment CF, in agreement with observations in long-term testicular cancer survivors. 7 In general, neuroticism has only rarely been evaluated in connection with the treatment of prostate cancer. However, a recent study by Van den Bergh et al. 34 for the first time described the negative impact of high neuroticism on Table 3 Medical and socio-demographic characteristics (A), functional assessments (B) and fatigue measures (C) by treatment groups at the time of survey
12, o20 69 (21) 41 (22) 110 (21) Fatigue in hormone-naïve prostate cancer survivors AE Kyrdalen et al the feasibility of active surveillance in low-risk prostate cancer patients. About half of our hormone-naïve patients, regarded to be tumor-free at the time of the survey, reported some degree of pain, with significant association with CF. This indicates that any attempts to reduce post-treatment fatigue after RP and RAD have to include the assessment and treatment of the patient's pain experience even though pain at this phase of the malignancy is not related to the presence of metastases.
The finding of an inverse relation between age and CF within the prostate cancer cohort is surprising, as CF, and probably the susceptibility for CF, generally increases with increasing age. Our observation may be explained as follows: With today's pretreatment counseling, where CF is usually not mentioned, young otherwise healthy prostate cancer patients do probably not expect fatigue after today's short hospitalization periods. Being unprepared for this post-treatment adverse effect, even slight changes of vitality and persisting degrees of fatigue might be experienced as CF, more so by younger than older men. Our results are in agreement with observations from testicular cancer survivors showing that older men cope better with fatigue than younger ones. 7 Litwin et al. 35 showed in a longitudinal study that the difference in vitality between RP and RAD survivors increased over time as RP survivors regained vitality, while no changes were observed among RAD survivors after 24 months. In our cross-sectional study, we found the highest prevalence of CF in RAD patients with the longest observation time.
Post-treatment urinary and intestinal problems remained significantly associated with CF in the multivariate analysis, indicating that the burden from these symptoms may be stressful for the patient. While sexual function might be associated with other aspects of quality of life, it is not independently associated with reporting CF.
The etiology of fatigue is unknown, but proinflammatory processes, autonomic instability and/or disturbances of the pituitary-adrenal axis have been discussed. 36 In this cross-sectional study, without baseline data we can only speculate about the reasons of elevated long-term CF in the RAD group. Except age, the variations in pretreatment demographic and medical variables seemed to have minor effect on this difference. Our data might thus reflect a true etiological factor in the development of CF as a consequence of RAD. Probably more so than surgery, high-dose RAD induces long-lasting inflammatory processes, 37, 38 with chronic overproduction of cytokines with long-term development of fibrosis and necrosis in normal tissue. 39 
Strength and limitations
We view our results as generalizable since we analyzed a large population-based cohort of hormone-naïve prostate cancer survivors, while most other comparable studies are performed involving patients from single Fatigue in hormone-naïve prostate cancer survivors AE Kyrdalen et al institutions. Whereas other studies have controlled use of hormones using statistical measures, 9 we excluded ever-ADT users and could thus analyze the impact of curative local treatment only, for the prevalence of post-treatment fatigue. We regard the use of a validated and specific fatigue instrument to be an advantage of our study.
An appropriate attrition analysis could not be performed due to lack of NorPD data for non-compliant patients. The largest limitation of our cross-sectional study is the fact that we have limited information about patient's pretreatment medical condition. Fatigue and comorbidity may have been a larger pretreatment problem in RAD than RP patients, but have remained undetected in this survey particularly as we only had limited information on pretreatment co-morbidity.
Conclusions
After a median of 23 months a significantly lower proportion of prostate cancer patients reported CF after RP as compared with RAD. Lower age, presence of high neuroticism, post-treatment co-morbidity, pain and urinary and intestinal dysfunction were significantly associated with reporting CF when adjusted for possible confounders. For further research of CF, prospective studies are needed, which take into account the survivors' pretreatment medical and psychosocial situation.
